GKV Capital Management Co. Inc. Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GKV Capital Management Co. Inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,835 shares of the biopharmaceutical company's stock, valued at approximately $2,732,000. Regeneron Pharmaceuticals comprises approximately 1.1% of GKV Capital Management Co. Inc.'s holdings, making the stock its 27th biggest position.

Several other institutional investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its position in shares of Regeneron Pharmaceuticals by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after acquiring an additional 155,369 shares during the last quarter. Dodge & Cox raised its holdings in shares of Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock valued at $1,653,543,000 after buying an additional 9,381 shares during the last quarter. Franklin Resources Inc. grew its holdings in Regeneron Pharmaceuticals by 7.9% in the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock worth $1,456,864,000 after buying an additional 149,124 shares in the last quarter. Loomis Sayles & Co. L P increased its position in Regeneron Pharmaceuticals by 33.4% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after acquiring an additional 393,997 shares during the period. Finally, Amundi raised its stake in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after acquiring an additional 487,489 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 4.1 %

Shares of REGN stock traded up $22.89 on Tuesday, reaching $584.38. The company had a trading volume of 311,890 shares, compared to its average volume of 712,397. The company has a 50-day moving average of $643.90 and a 200-day moving average of $733.36. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20. The stock has a market cap of $63.89 billion, a PE ratio of 15.26, a PEG ratio of 2.34 and a beta of 0.44. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $11.86 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.60%. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Analysts Set New Price Targets

REGN has been the subject of several recent analyst reports. TD Cowen decreased their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a report on Tuesday, February 4th. Sanford C. Bernstein reduced their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research report on Tuesday, February 4th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $950.76.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.